Vir projects cash runway into 2H 2028 as it expects ECLIPSE-1 top line data in Q3 2026

• President, CEO & Director Marianne De Backer said Vir is “entering a pivotal period for Vir Bio with the potential to transform hepatitis delta treatment while building a differentiated oncology franchise,” while highlighting leadership additions: “Aziz

Seeking Alpha's Disclaimer: This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.